Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic...
-
Upload
rolf-stewart -
Category
Documents
-
view
218 -
download
2
Transcript of Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic...
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III <br />RESONATETM Trial
Presented By John Byrd at 2014 ASCO Annual Meeting
Background
Presented By John Byrd at 2014 ASCO Annual Meeting
RESONATE™ Phase 3 Study Design
Presented By John Byrd at 2014 ASCO Annual Meeting
Study Objectives
Presented By John Byrd at 2014 ASCO Annual Meeting
Inclusion Criteria
Presented By John Byrd at 2014 ASCO Annual Meeting
Patient Disposition
Presented By John Byrd at 2014 ASCO Annual Meeting
Baseline Characteristics
Presented By John Byrd at 2014 ASCO Annual Meeting
Progression-Free Survival
Presented By John Byrd at 2014 ASCO Annual Meeting
Progression-Free Survival by Baseline Characteristics and Molecular Features
Presented By John Byrd at 2014 ASCO Annual Meeting
Overall Survival
Presented By John Byrd at 2014 ASCO Annual Meeting
Overall Response to Therapy: <br />IRC and Investigator Assessment
Presented By John Byrd at 2014 ASCO Annual Meeting
Best IRC Response without Second CT Confirmation
Presented By John Byrd at 2014 ASCO Annual Meeting
Safety: Adverse Events (≥15%) Regardless of Attributiona
Presented By John Byrd at 2014 ASCO Annual Meeting
Safety Overview
Presented By John Byrd at 2014 ASCO Annual Meeting
Safety: Atrial Fibrillation and Bleeding-Related Adverse Events
Presented By John Byrd at 2014 ASCO Annual Meeting
Conclusions
Presented By John Byrd at 2014 ASCO Annual Meeting
Acknowledgments
Presented By John Byrd at 2014 ASCO Annual Meeting
Acknowledgments
Presented By John Byrd at 2014 ASCO Annual Meeting